As a histamine H1 receptor antagonist, this product can counteract the capillary dilation caused by allergic reactions, reduce the permeability of capillaries, and relieve wheezing caused by bronchial smooth muscle contraction. This product has a long-lasting antihistamine effect and also has a significant central inhibitory effect, which can increase the effects of anesthetics, analgesics, hypnotics and local anesthetics. This product is mainly metabolized in the liver.

Cephalexin is a first-generation cephalosporin with an antibacterial spectrum similar to that of cephalothin, but its antibacterial activity is poorer than that of the latter. Except for Enterococcus and methicillin-resistant Staphylococci, most strains of Streptococcus pneumoniae, hemolytic Streptococcus, and Staphylococcus aureus that produces or does not produce penicillinase are sensitive to this product. This product has a good antibacterial effect on Neisseria, but Haemophilus influenzae is less sensitive to this product; this product has a certain antibacterial effect on some Escherichia coli, Proteus mirabilis, Salmonella and Shigella. The remaining Enterobacteriaceae, Acinetobacter, Pseudomonas aeruginosa, and Bacteroides fragilis are resistant to this product. Fusobacterium and Veillonella are generally sensitive to this product, and anaerobic Gram-positive cocci are moderately sensitive to this product.

This product is a gastrin receptor antagonist, which can significantly inhibit the secretion of gastric acid and pepsin caused by gastrin, but has no obvious effect on the gastric acid secretion caused by histamine and vagus nerve stimulation. It can increase the content of hexosamine in the gastric mucosa, promote glycoprotein synthesis, protect and promote the healing of the gastric mucosa, improve the symptoms of peptic ulcer and promote the healing of ulcer. The use of this product to treat peptic ulcer and gastritis does not cause rebound of gastric acid secretion, and gastric acid secretion can remain at a normal level for up to half a year after the treatment is terminated. In addition, this product has a choleretic effect, preventing stone formation by stimulating bile acid-independent bile secretion, changing the stone-forming factors in bile, and antagonizing CCK.

This product is a broad-spectrum semi-synthetic penicillin with extremely low toxicity. The antibacterial spectrum is similar to that of penicillin, and it has a strong antibacterial effect on grass-green streptococci, hemolytic streptococci, and enterococci. Diphtheria bacillus, anthrax bacillus, gram-positive anaerobic cocci and bacilli are sensitive to this product; meningococci, pertussis bacillus, and brucella are also very sensitive. Escherichia coli, Salmonella, Shigella dysenteriae, Proteus, influenza bacillus, pneumococci, gonococci, etc. have different degrees of drug resistance because some strains produce beta-lactamase. Among them, the drug resistance rate of Escherichia coli is as high as 50-60%. Enterobacter bacteria, Pseudomonas aeruginosa and anaerobic Gram-negative bacilli are resistant to this product. It is mainly used to treat infectious diseases caused by sensitive Staphylococcus aureus, hemolytic streptococci, gonococci, meningococci, diphtheria bacillus, pertussis bacillus, influenza bacillus, Salmonella, Shigella, etc.

This product is a broad-spectrum semi-synthetic penicillin with extremely low toxicity. The antibacterial spectrum is similar to that of penicillin, and it has a strong antibacterial effect on grass-green streptococci, hemolytic streptococci, and enterococci. Diphtheria bacillus, anthrax bacillus, Gram-positive anaerobic cocci and bacilli are sensitive to this product; meningococci, pertussis bacilli, and Brucella are also very sensitive. Escherichia coli, Salmonella, Shigella dysenteriae, Proteus, influenza bacilli, pneumococci, gonococci, etc., all have varying degrees of drug resistance because some strains produce beta-lactamase. Among them, the resistance rate of Escherichia coli is as high as 50-60%. Enterobacter bacteria, Pseudomonas aeruginosa, and anaerobic Gram-negative bacilli are resistant to this product. This product is mainly used to treat infectious diseases caused by sensitive Staphylococcus aureus, hemolytic streptococci, gonococci, meningococci and diphtheria Bordetella, pertussis Bordetella, influenza Bordetella, Salmonella, Shigella, etc.; such as respiratory tract infections (pneumonia, acute and chronic bronchitis, whooping cough, etc.), gastroenteritis and digestive tract infections (liver and gallbladder infections, acute and chronic gastroenteritis, bacillary dysentery, typhoid and paratyphoid, etc.), urinary tract infections (gonorrhea, urethritis, cystitis, etc.), soft tissue infections and sepsis, meningitis, endocarditis, etc.